Jon P. Stonehouse - Feb 1, 2023 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
President & CEO, Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Feb 1, 2023
Transactions value $
-$493,000
Form type
4
Date filed
2/2/2023, 04:20 PM
Previous filing
Jan 5, 2023
Next filing
Mar 23, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Gift $0 -10K -0.98% $0.00 1.01M Dec 29, 2022 Direct F1
transaction BCRX Common Stock Gift $0 +5K +100% $0.00 10K Dec 29, 2022 By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust F1
transaction BCRX Common Stock Gift $0 +5K +100% $0.00 10K Dec 29, 2022 By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust F1
transaction BCRX Common Stock Options Exercise $545K +100K +9.91% $5.45 1.11M Feb 1, 2023 Direct F2
transaction BCRX Common Stock Sale -$1.04M -100K -9.02% $10.38 1.01M Feb 1, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -100K -100% $0.00* 0 Feb 1, 2023 Common Stock 100K $5.45 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 29, 2022, the reporting person gifted 5,000 shares held directly by him to each of the Samuel Stonehouse Irrevocable Trust and the Caroline Stonehouse Irrevocable Trust.
F2 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on August 8, 2013 and would have expired on August 8, 2023. The shares sold subsequent to the exercise of such options represent less than 2% of the reporting person's holdings of the issuer's securities.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.22 to $10.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The options vested upon the achievement of performance-based vesting criteria with respect to 25,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020.